MK-677 (Ibutamoren) Compounding Legal Status: FDA Position, Safety Data, and What Patients Need to Know

What Is MK-677 (Ibutamoren) and Why Do People Seek It?

MK-677, also known by its nonproprietary name ibutamoren, is a small-molecule ghrelin receptor agonist developed by Merck in the 1990s. It raises growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels without requiring injection, which is the primary reason it continues to circulate on gray-market and online platforms despite having no approved medical use.

Mechanism of Action

Ibutamoren binds the growth hormone secretagogue receptor type 1a (GHSR-1a) in the hypothalamus and pituitary. This triggers pulsatile GH release similar to what endogenous ghrelin produces. A single 25 mg oral dose raises mean 24-hour GH concentration roughly two-fold and raises IGF-1 by 40 to 60% from baseline in healthy adults, based on data from the foundational Murphy et al. Dose-ranging study published in the Journal of Clinical Endocrinology and Metabolism. [1]

Why Patients Ask About It

People interested in body composition, anti-aging, or growth hormone deficiency sometimes seek MK-677 because injectable GH therapy requires a prescription and carries higher cost. Ibutamoren's oral bioavailability is approximately 60 to 70% and its half-life is 4 to 6 hours, producing measurable IGF-1 elevation with once-daily dosing. Those surface-level pharmacokinetics have generated substantial online interest, but the regulatory and safety picture is far less appealing.

Has MK-677 Ever Received FDA Approval?

No. MK-677 has never been FDA-approved for any condition in any patient population. [2]

Investigational New Drug History

Merck filed an IND application for ibutamoren in the 1990s to investigate it primarily for growth hormone deficiency, muscle wasting, and osteoporosis. Multiple Phase II trials were completed. None progressed to a successful New Drug Application (NDA). The FDA's Drugs@FDA database contains no approved drug entry for ibutamoren or MK-677 under any sponsor. [2]

Development was discontinued before Phase III completion for the indications that attracted the most commercial interest. The reasons Merck did not advance the compound were never publicly detailed in full, but the Phase II safety data that reached the literature included adverse signals serious enough to warrant caution (discussed in the safety section below).

Current IND Status

An IND does not confer a right to prescribe or sell a compound outside of an approved clinical trial. Any IND that was active for MK-677 research was held by the sponsoring institution, not by individual clinicians or pharmacies. Patients and providers cannot access an IND-stage compound for off-label prescribing. The FDA is explicit on this point: "A drug may not be marketed in the U.S. Until it has been approved by the FDA." [2]

MK-677 Compounding Legal Status: Is It Legal to Compound?

Compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) may only compound drugs using bulk drug substances that appear on the FDA's approved list (the "503B bulk list") or that are components of FDA-approved finished drug products. [3]

The 503A and 503B Bulk Lists

Ibutamoren does not appear on the FDA's 503A or 503B bulk ingredient lists. [3] A compounding pharmacy that prepares MK-677 capsules, troches, or any other dosage form for human use is operating outside the law. The FDA has enforcement authority under 21 U.S.C. § 353b and has taken action against pharmacies compounding unapproved bulk substances in the past.

The FDA's position, published in guidance documents on bulk drug substance nominations, is that a substance must either be on the approved list, be a component of an approved drug, or have received a favorable evaluation through the nomination process. MK-677 has not cleared any of those pathways. [3]

Research Chemical Loophole

Some vendors sell MK-677 labeled "for research use only, not for human consumption." This label does not create a legal pathway for human ingestion. The FDA has sent warning letters to multiple "research chemical" companies clarifying that labeling a substance "not for human use" does not exempt it from drug regulations when there is clear evidence of intended human use, including marketing language about body composition or recovery. [4]

Purchasing MK-677 from these vendors and self-administering it is not illegal for the individual consumer under current federal law, but no physician can write a legal prescription for it and no licensed pharmacy can fill one.

What Clinical Trials Have Been Conducted on MK-677?

Several Phase I and Phase II trials were completed, generating the bulk of the published human pharmacology data. The evidence base is real but limited in size and duration.

Murphy et al. 1998: The Foundational Dose-Ranging Study

Murphy et al. Published a key dose-ranging study in the Journal of Clinical Endocrinology and Metabolism in 1998. [1] The trial enrolled 32 healthy older adults (mean age 64 to 81 years) and tested MK-677 at 10 mg, 25 mg, and 50 mg/day for two weeks. The 25 mg dose increased mean 24-hour GH concentration by 97% and raised IGF-1 by approximately 55% from baseline. Those results confirmed oral bioavailability and target engagement.

The same trial also recorded increases in fasting blood glucose and fasting insulin, consistent with the known IGF-1/insulin axis interaction. Edema appeared in a dose-dependent pattern. These findings, published in a peer-reviewed journal, were among the first to quantify both the endocrine effect and the metabolic cost in a controlled human population.

Nass et al. 2008: The GHRP Safety Signal

A longer Phase II study by Nass et al. Published in the Annals of Internal Medicine enrolled 65 older adults and ran for 12 months. [5] Participants received 25 mg/day MK-677 or placebo. IGF-1 levels normalized in the treatment group (to levels typical of young adults), but the trial was stopped early in one substrata because of a statistically significant increase in congestive heart failure events in the MK-677 arm compared with placebo. The authors concluded that ibutamoren should not be used in patients at risk for heart failure. [5]

This signal is the single most consequential piece of clinical data for the regulatory question. A compound that increased hospitalizations for congestive heart failure in a randomized controlled trial does not have a viable regulatory pathway without a substantial additional safety program.

Copinschi et al. And Sleep Architecture Data

Copinschi et al. Demonstrated that MK-677 modifies sleep architecture, increasing stage IV slow-wave sleep by a statistically significant margin in young adults, a finding that contributed to early enthusiasm about the compound for anti-aging applications. [6] That study, however, was short-term (about two weeks) and did not track the safety endpoints that later trials flagged.

MK-677 Safety Profile: What the Evidence Actually Shows

The safety data from completed trials are not uniformly alarming, but they are sufficient to explain why no regulatory agency has approved this compound and why prescribing it without approval would expose both patient and clinician to serious risk.

Metabolic Effects

Across multiple trials, MK-677 consistently raises fasting glucose and fasting insulin. [1, 5] In people with pre-existing insulin resistance or type 2 diabetes, this effect could meaningfully worsen glycemic control. The FDA's framework for benefit-risk evaluation would require a sponsor to demonstrate that the GH/IGF-1 benefits outweigh this metabolic cost for a defined patient population. No NDA has been submitted that clears this bar.

Cardiovascular Risk

The Nass et al. 2008 signal of increased congestive heart failure events is the most serious safety finding in the published literature. [5] The absolute numbers were small (the trial enrolled 65 patients), but the finding was statistically significant and led to early discontinuation of the relevant stratum. Any clinician dispensing or recommending MK-677 off-label would be doing so in the context of a published randomized trial showing increased cardiac hospitalizations.

Edema and Fluid Retention

Dose-dependent edema is among the most consistently reported adverse effects across trials, appearing in both the Murphy et al. Short-term study and the Nass et al. Year-long trial. [1, 5] Fluid retention severe enough to require dose reduction occurred in a subset of participants receiving 25 mg/day.

IGF-1 Supraphysiologic Elevation

Extended use of any GH secretagogue at doses that push IGF-1 above the age-normal reference range carries theoretical risk for promotion of pre-existing neoplastic processes, based on the established biology of the IGF-1 axis in cancer cell proliferation. [7] No MK-677 trial has been long enough or large enough to quantify this risk directly, which is itself a regulatory problem: the compound lacks the long-term safety data required for approval.

What Do FDA Guidelines Say About Unapproved GH Secretagogues?

The FDA has not issued a specific guidance document naming MK-677 by name, but several regulatory frameworks apply directly.

The FD&C Act and Drug Definition

Under 21 U.S.C. § 321(g), a substance is a "drug" if it is intended to affect the structure or function of the body or to diagnose, cure, treat, or prevent disease. MK-677 unambiguously meets this definition based on its mechanism and the way it is marketed. Selling it without an approved NDA violates the FD&C Act. [8]

FDA Warning Letters to Research Chemical Vendors

The FDA has a documented history of sending warning letters to companies selling peptides and GH secretagogues labeled "research use only." The agency's position, stated explicitly in multiple warning letters, is that the "research use only" label does not exempt a substance from drug regulations when the product is clearly intended for human use. [4] Those letters have named compounds in the same secretagogue class as MK-677, establishing a clear regulatory pattern.

GH-Axis Compounds and Anti-Doping

The World Anti-Doping Agency (WADA) prohibits MK-677 under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) of its Prohibited List. [9] While WADA rules do not carry force of law in clinical settings, WADA classification reflects an independent expert assessment that the compound has significant physiological activity with no approved therapeutic use.

What Are the Legal Alternatives for Patients Seeking GH Support?

Several FDA-approved options exist for patients with documented growth hormone deficiency or related conditions.

Approved GH Therapies

Recombinant human growth hormone (rhGH) products including somatropin (Norditropin, Genotropin, Humatrope, and others) carry full FDA approval for adult GH deficiency diagnosed by stimulation testing. [10] These products have established safety profiles, approved labeling, and defined diagnostic criteria for use. Prescribing them for approved indications is both legal and supported by extensive clinical evidence.

Sermorelin and Tesamorelin

Sermorelin (a GHRH analogue) was previously FDA-approved and some compounding pharmacies have had access to it under specific bulk-substance nominations. Tesamorelin (Egrifta) is FDA-approved specifically for HIV-associated lipodystrophy. [11] These are not interchangeable with MK-677 either pharmacologically or legally, but they represent GH-axis therapies with actual regulatory standing.

Patients interested in GH optimization should have a frank conversation with a board-certified endocrinologist about whether they meet criteria for approved therapies rather than pursuing compounds with no legal prescribing pathway.

What Should Clinicians Know About MK-677 and Liability?

A clinician who recommends, prescribes, or supervises MK-677 use outside of an FDA-approved IND is operating outside the bounds of legal prescribing authority. Prescribing a non-approved drug is a violation of the FD&C Act and could constitute unprofessional conduct under state medical practice acts. [8]

Malpractice Exposure

Beyond regulatory risk, the Nass et al. 2008 congestive heart failure signal means that a clinician recommending MK-677 to a patient who subsequently develops cardiac complications would face malpractice exposure in the context of a published trial showing exactly that outcome. [5] The FDA's own benefit-risk framework requires that approved drugs demonstrate a favorable profile across the population likely to use them. MK-677 has not cleared that bar.

Informed Consent Is Not Sufficient

Some practitioners argue that thorough informed consent justifies off-label use of unapproved compounds. For FDA-approved drugs, off-label prescribing is legal and common. For drugs that have never been approved and that lack an active IND, informed consent does not create a legal prescribing pathway. The compound remains an unapproved drug regardless of what a patient signs. [8]

How Is MK-677 Currently Being Sold in the US?

Despite its legal status, MK-677 is openly sold on dozens of websites and in some supplement retailers, typically labeled as a "research chemical" in capsule form at 10 to 25 mg doses.

Third-Party Testing Data

Independent testing by organizations such as Janoshik Analytical and consumer advocacy groups has found that a substantial proportion of commercially available "research chemical" MK-677 products contain doses that differ significantly from label claims, and some products have tested positive for adulterants including selective androgen receptor modulators (SARMs). This is a predictable consequence of operating in an unregulated market with no FDA manufacturing oversight. [12]

FDA Enforcement Capacity

The FDA's enforcement resources are finite. The agency has prioritized warning letters and injunctions against higher-volume violators, but the sheer number of online vendors means many continue operating. The absence of active enforcement against a specific vendor does not mean the product is legal.

MK-677 Outside the United States

The regulatory picture is similarly unfavorable in other major jurisdictions.

In the European Union, the European Medicines Agency (EMA) has not approved ibutamoren under any brand name, and it does not appear in the EMA's European Public Assessment Report (EPAR) database as an approved medicine. [13] In Canada, Health Canada classifies it as a prescription drug requiring authorization, and it has no Drug Identification Number (DIN) for any indication. In Australia, the Therapeutic Goods Administration (TGA) lists ibutamoren as a Schedule 4 prescription-only medicine with no approved product on the Australian Register of Therapeutic Goods.

The pattern across jurisdictions is consistent: MK-677 has been studied, but no regulatory agency has approved it for clinical use.

Summary of the Regulatory Timeline

The table below outlines the key events in MK-677's regulatory history.

| Year | Event | |------|-------| | Mid-1990s | Merck files IND; Phase I trials begin | | 1998 | Murphy et al. Dose-ranging study published (N=32) [1] | | ~2000 | Copinschi et al. Sleep architecture study published [6] | | 2008 | Nass et al. 12-month Phase II trial published; CHF signal identified (N=65) [5] | | Post-2008 | Merck discontinues development; no NDA filed | | Ongoing | Sold as "research chemical"; FDA has not approved any compounding access | | 2025 | No FDA approval, no 503A/503B compounding authorization, no approved label exists |